tolterodine + solifenacin

Tolterodine + solifenacin refers to a treatment regimen involving the sequential or comparative use of two antimuscarinic agents, tolterodine and solifenacin, primarily for the management of overactive bladder syndrome (OAB). This specific context is associated with clinical research conducted at National Taiwan University Hospital (NTUH) to evaluate the psychiatric, cardiovascular, and prognostic effects of these therapies in female patients. Tolterodine is a competitive muscarinic receptor antagonist that acts non-selectively across M1-M5 receptor subtypes, while solifenacin is a competitive antagonist with higher selectivity for the M3 receptor subtype. Both drugs function by inhibiting acetylcholine-mediated contractions of the detrusor smooth muscle in the bladder, thereby increasing bladder capacity and reducing symptoms such as urgency, frequency, and urge incontinence. The NTUH study specifically investigated factors such as heart rate variability, arterial stiffness, and psychiatric predispositions in patients receiving these treatments.

Other names

tolterodine and solifenacin